An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetic and safety profiles of
omacetaxine and its metabolites in patients with relapsed and/or refractory hematologic
malignancies or advanced solid tumors following subcutaneous (sc) administration.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries